Alta Neuroscience

Neurons in the brain
#Alta Neuroscience #Alzheimer's #Biomarkers #Blood-based biomarkers #Diagnostics #Roche

How Roche is advancing Alzheimer’s research

DDW’s Megan Thomas speaks with Dr Maria-Magdalena Patru, Scientific Partner at Roche Diagnostics US, about how advances in Alzheimer’s disease (AD), particularly blood-based biomarkers (BBM), can enable earlier, more accurate, and accessible detection of the disease, supporting timely treatment and improved patient outcomes.  MT: Why is improving AD diagnostics crucial… Read More

#Exclusive Content

#Alta Neuroscience #Depression #Major depressive disorder #Neuroscience #Phase II trial

Major depressive disorder drug progresses to Phase II trials

Alto Neuroscience has initiated a Phase II study to determine the pharmacodynamic effects of ALTO-203 in major depressive disorder (MDD) patients, as well as assess its safety, tolerability, and pharmacokinetics. To date, ALTO-203 has demonstrated positive emotional and cognitive effects in healthy participants after a single… Read More

#News

Patient speaking to psychiatrist
#Alta Neuroscience #Biomarkers #Major depressive disorder #Neuroscience #Phase II trial #Precision psychiatry #Psychiatry

Precision drug could redefine depression treatment

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More

#News